+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Neurology Market: A Research Overview

  • ID: 4804131
  • Report
  • July 2019
  • Region: Global
  • 194 Pages
  • BCC Research
1 of 5

FEATURED COMPANIES

  • Abbvie
  • Astrazeneca Plc
  • Bristol-Myers Squibb Co.
  • Gedeon Richter Plc
  • Lupin Ltd.
  • Otsuka Holdings Co., Ltd.
  • MORE

Report Scope:

The scope of this report is broad and covers therapeutics used in the treatment of neurological disorders.

The report highlights the current and future market potential of neurology medicines and provides a detailed analysis of the competitive environment, regulations, epidemiology of neurological diseases, merger and acquisition, drivers, restraints, and pipeline drugs in the market. The report also covers market projections through 2024.

The report details market shares of neurology based on different disease indication. Based on neurological disorders the market is segmented into Parkinson Diseases, Alzheimer Diseases, Psychotic Disorders, Epileptic Disorders, Autism Disorders, and Brain Tumor Diseases. Each diseases segment covers therapeutics and regional analysis.

The market for Parkinson Diseases covers anti-Parkinson’s drugs. The market is segmented into drug class and region. Based on drug class the market is segmented into dopaminergic, enzyme inhibitors, dopamine agonists and other Anti-Parkinson’s medications. Based on the region the market is segmented into North America, Europe, Asia-Pacific, South America and the Middle East and Africa.

The market for Alzheimer Diseases covers anti-Alzheimer drugs. the market is segmented based on the mechanism of action of drugs and region. based on drug class the market is segmented into AChE inhibitors and NMDA antagonist. Based on the region the market is segmented into North America, Europe, and Rest of the World.

The market of psychotic diseases covers antipsychotic drugs. The market is segmented into drug class and region. Based on the drug, the market is segmented into D2 antagonists, D2/5HT2A antagonists, and D2 partial agonist. Based on the region the market is segmented into North America, Europe, Asia-Pacific, South America and the Middle East and Africa.

The market for Epileptic Diseases covers Anti-Epileptic Drugs. The market is segmented into drug class and region. Based on drug class the market is segmented into first generation drugs, second generation drugs, and third generation drugs. Based on the region the market is segmented into North America, Europe, Asia-Pacific, South America and the Middle East and Africa.

The market for autism disorder covers autism disorder therapeutics. The market is segmented into drug based on labeled information and region. Based on drug class the market is segmented into ASD-labeled pharmaceuticals and Off-label pharmaceuticals. Based on the region the market is segmented into North America, Europe, and Rest of the World.

The market of brain tumor covers brain tumor therapeutics. The market is segmented into therapy type and region. Based on the therapy type, the market is segmented into chemotherapy and targeted therapy. Based on the region, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World.

For market estimates, data is provided for 2018 as the base year, with forecasts for 2019 through 2024. Estimated values are based on drug manufacturers’ total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

The Report Includes:

  • 15 data tables and 22 additional tables
  • An in-depth overview and industry analysis of the global market for neurology medicines
  • Analyses of the global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024
  • Historical background on neurological disorders and therapeutics, growing prevalence of neurological disorders, increasing research and development activities regarding neurology research, and analysis of the factors influencing the market
  • Quantitative analysis of the neurology therapeutics market covering Parkinson Diseases, Alzheimer Diseases, Psychotic Disorders, Epileptic Disorders, Autism Disorders, and Brain Tumor Diseases
  • Discussion of various therapeutics used for the treatment of different neurological disorders, along with coverage of novel pipeline, patent expiry of blockbuster drug and new drug approvals
  • Reviews of the competitive landscape, key strategies adopted by market players, mergers and acquisitions details, pipeline analysis covering ongoing clinical trials and promising forthcoming neuroscience therapies in late-stage, etc.
  • Details company profile of leading participants within the neurology market including, AbbVie, Biogen, GlaxoSmithKline Plc, Johnson & Johnson, and Sun Pharmaceuticals Industries Ltd.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbvie
  • Astrazeneca Plc
  • Bristol-Myers Squibb Co.
  • Gedeon Richter Plc
  • Lupin Ltd.
  • Otsuka Holdings Co., Ltd.
  • MORE

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing this Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Custom Research
  • Related Reports

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

  • Neurological Disorders: Overview
  • Disease Background
  • Parkinson Disease
  • Alzheimer Disease
  • Schizophrenia
  • Bipolar Disorders
  • Depression
  • Epileptic Disorders
  • Autism Spectrum Disorders
  • Neuroprotective Agents
  • Neuroprotective Strategies
  • Drug Development Regulations
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Asia-Pacific
  • ROW
  • Reimbursement Landscape

Chapter 4 Market Dynamics

  • Market Drivers
  • Government and NGO Initiatives in Creating Awareness
  • Growing Geriatric Population with Neurological Disorders
  • Increasing Global Incidence of Neurological Disorders
  • Research Initiatives in Neurology
  • Accelerated Approvals for Drugs Used in Rare Diseases
  • Market Restraints
  • Patent Expirations of Branded Drugs and Emergence of Generics
  • Adverse Side Effects
  • High Cost of Drug Development

Chapter 5 Global Market for Neurology

  • Global Market for Neurology, by Disease Indication

Chapter 6 Global Market for Parkinson Disease

  • Anti-Parkinson’s Drugs: Market Overview
  • Anti-Parkinson’s Drugs Market, by Drug Class
  • Dopaminergic
  • Market Size and Forecast
  • Market Analysis
  • Dopamine Agonists
  • Market Size and Forecast
  • Market Analysis
  • Enzyme Inhibitors Market
  • Market Size and Forecast
  • Market Analysis
  • Other Anti-Parkinson’s Drugs
  • Market Size and Forecast
  • Market Analysis
  • Anti-Parkinson’s Drugs Market, by Region
  • North America
  • Market Size and Forecast
  • Market Analysis
  • Europe
  • Market Size and Forecast
  • Market Analysis
  • Asia-Pacific
  • Market Size and Forecast
  • Market Analysis
  • South America
  • Market Size and Forecast
  • Market Analysis
  • Middle East and Africa
  • Market Size and Forecast
  • Market Analysis
  • Global Company Share Analysis

Chapter 7 Global Market for Alzheimer Disease

  • Market Overview
  • Global Alzheimer Drugs Market, by Mechanism of Action
  • AChEIs
  • Market Size and Forecast
  • Market Analysis
  • NMDA Drugs
  • Market Size and Forecast
  • Market Analysis
  • Global Alzheimer Drugs Market, by Region
  • North America
  • Market Size and Forecast
  • Market Analysis
  • Europe
  • Market Size and Forecast
  • Market Analysis
  • Rest of the World
  • Market Size and Forecast
  • Market Analysis
  • Industry Structure
  • Impact of Generic AD Therapeutics

Chapter 8 Global Market for Psychotic Disorders

  • Market Overview
  • Global Antipsychotic Drugs Market, by Drug Class
  • D2 Antagonists
  • Market Size and Forecast
  • Market Analysis
  • D2/5HT2A Antagonists
  • Market Size and Forecast
  • Market Analysis
  • D2 Partial Agonists
  • Market Size and Forecast
  • Market Analysis
  • Global Antipsychotic Drugs Market, by Region
  • North America
  • Market Size and Forecast
  • Market Analysis
  • Europe
  • Market Size and Forecast
  • Market Analysis
  • Asia-Pacific
  • Market Size and Forecast
  • Market Analysis
  • South America
  • Market Size and Forecast
  • Market Analysis
  • Middle East and Africa
  • Market Size and Forecast
  • Market Analysis
  • Global Company Share Analysis
  • Impact of Generic Antipsychotic Drugs on the Market

Chapter 9 Global Market for Epileptic Disorders

  • Market Overview
  • Market Trends
  • Global Anti-Epileptic Drugs Market, by Drug Class
  • First Generation Anti-Epileptic Drugs
  • Market Size and Forecast
  • Market Analysis
  • Second Generation Anti-Epileptic Drugs
  • Market Size and Forecast
  • Market Analysis
  • Third Generation Anti-Epileptic Drugs
  • Market Size and Forecast
  • Market Analysis
  • Global Anti-Epileptic Drugs Market, by Region
  • North America
  • Market Size and Forecast
  • Market Analysis
  • Europe
  • Market Size and Forecast
  • Market Analysis
  • Asia-Pacific
  • Market Size and Forecast
  • Market Analysis
  • South America
  • Market Size and Forecast
  • Market Analysis
  • Middle East and Africa
  • Market Size and Forecast
  • Market Analysis
  • Anti-Epileptic Drugs Market Competitive Landscape

Chapter 10 Global Market for Autism Spectrum Disorders

  • Market Overview
  • Antipsychotics
  • Antidepressants
  • Stimulants
  • Anticonvulsants
  • Global ASD Therapeutics Market, by Label Information
  • Labeled ASD Pharmaceuticals
  • Market Size and Forecast
  • Market Analysis
  • Off-label Pharmaceuticals
  • Market Size and Forecast
  • Market Analysis
  • Global ASD Therapeutics Market, by Region
  • North America
  • Market Size and Forecast
  • Market Analysis
  • Europe
  • Market Size and Forecast
  • Market Analysis
  • Rest of the World
  • Market Size and Forecast
  • Market Analysis
  • Global ASD Therapeutics Market Industry Structure

Chapter 11 Global Market for Brain Tumor Therapeutics

  • Market Overview
  • Brain Tumor Therapeutics Market, by Therapy Type
  • Chemotherapy
  • Market Size and Forecast
  • Market Analysis
  • Targeted Therapy
  • Market Size and Forecast
  • Market Analysis
  • Immunotherapy
  • Immunotherapeutic Agents
  • New Developments
  • Brain Tumor Therapeutics Market, by Region
  • North America
  • Market Size and Forecast
  • Market Analysis
  • Europe
  • Market Size and Forecast
  • Market Analysis
  • Asia-Pacific
  • Market Size and Forecast
  • Market Analysis
  • Rest of the World
  • Market Size and Forecast
  • Market Analysis
  • Company Share Analysis

Chapter 12 Pipeline Analysis

  • Overview of the Drug Development Process

Chapter 13 Competitive Landscape

  • Key Strategies Adopted by Market Players
  • Mergers and Acquisitions
  • Agreements and New Product Launches

Chapter 14 Company Profiles

  • Abbvie
  • Acadia Pharmaceuticals, Inc.
  • Alembic Pharmaceuticals Ltd.
  • Alexza Pharmaceuticals
  • Alkermes Plc
  • Allergan Plc
  • Apotex, Inc.
  • Astrazeneca Plc
  • Aurobindo Pharma
  • Autism Therapeutics
  • Avanir Pharmaceuticals Inc.
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Co.
  • Biogen
  • Daiichi Sankyo Co., Ltd.
  • Dr. Reddy’S Laboratories Ltd.
  • Eli Lilly And Co.
  • Eisai Co. Ltd.
  • F. Hoffmann-La Roche Ag
  • Glaxosmithkline Plc
  • Gedeon Richter Plc
  • Immunocellular Therapeutics, Ltd.
  • Johnson & Johnson
  • Lannett Co., Inc.
  • H. Lundbeck A/S
  • Lupin Ltd.
  • Mallinckrodt
  • Merck & Co
  • Mylan Nv
  • Nextsource Biotechnology Llc
  • Novartis Ag
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Sanofi
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Sun Pharmaceutical Industries Ltd. (Sun Pharma)
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • United Therapeutics Corp.
  • UCB SA

Chapter 15 Appendix: Acronyms

Chapter 16 References

List of Tables
Summary Table: Global Market for Neurology, by Disease Indication, Through 2024
Table 1: Current Orphan Drugs Designations for Brain Tumors
Table 2: Global Market for Neurology, by Disease Indication, Through 2024
Table 3: Global Neurology Market for Anti-Parkinson's Drugs, by Drug Class, Through 2024
Table 4: Global Neurology Market for Anti-Parkinson's Drugs, by Region, Through 2024
Table 5: Global Neurology Market for Alzheimer Drugs, by Mechanism of Action, Through 2024
Table 6: Global Neurology Market for Alzheimer Drugs, by Region, Through 2024
Table 7: Global Ranking of Leading Players in Alzheimer’s Disease Drugs, by Company
Table 8: Global Neurology Market for Antipsychotic Drugs, by Mechanism of Action, Through 2024
Table 9: D2 Antagonist Drugs: Market Presence
Table 10: Adverse Effects Profile of D2 Antagonist/Typical Antipsychotic Drugs
Table 11: Global Neurology Market for Antipsychotic Drugs, by Region, Through 2024
Table 12: Prevalence of Serious Mental Illness Among Adults in the U.S., by State, 2017
Table 13: Prevalence of Mental Illness in U.S., by Disease Indication, 2017
Table 14: Global Neurology Market for Anti-Epileptic Drugs, by Segment, Through 2024
Table 15: Global Neurology Market for Anti-Epileptic Drugs, by Region, Through 2024
Table 16: Global Neurology Market for ASD Therapeutics, by Label Information, Through 2024
Table 17: Selected Late-Stage Autism Treatments
Table 18: Global Neurology Market for ASD Therapeutics, by Region, Through 2024
Table 19: Global Market Ranking of Leading Players in ASD Drugs, by Company
Table 20: Global Neurology Market for Brain Tumor Therapeutics, by Therapy Type, Through 2024
Table 21: FDA-Approved Drugs Used in Brain Tumor Chemotherapy
Table 22: Dosage and Administration of Temozolomide for Brain Tumors
Table 23: Current Brain Tumor Clinical Trials: Temozolomide
Table 24: Current Brain Tumor Clinical Trials Involving Lomustine
Table 25: Current Brain Tumor Clinical Trials involving Carmustine
Table 26: PCV Regimen: Brain Tumor Chemotherapy
Table 27: FDA Approved Targeted Therapeutic Agents for Brain Tumors
Table 28: Monoclonal Antibodies
Table 29: Small Molecule Monoclonal Antibodies
Table 30: Current Brain Tumor Clinical Trials Involving Bevacizumab
Table 31: Current Brain Tumor Clinical Trials Involving Everolimus
Table 32: Current Brain Tumor Clinical Trials: Immunotherapy
Table 33: Global Neurology Market for Brain Tumor Therapeutics, by Region, Through 2024
Table 34: Promising Forthcoming Neuroscience Therapies in Late Stage
Table 35: Agents Currently in Phase III of Alzheimer’s Disease Drug Development, 2018
Table 36: Ongoing Clinical Trials and Product Pipeline Involving Major Players in Brain Tumor Therapeutics
Table 37: Acronyms Used in This Report

List of Figures
Summary Figure: Global Market Share for Neurology, by Disease Indication, 2018
Figure 1: Pharmaceutical Regulatory Pathways in the U.S and Europe
Figure 2: Global Market for Neurology, by Disease Indication, 2018-2024
Figure 3: Global Neurology Market Share for Anti-Parkinson's Drugs, by Drug Class, 2018
Figure 4: Global Neurology Market for Dopaminergic Drugs, 2018-2024
Figure 5: Global Neurology Market for Dopamine Agonist Drugs, 2018-2024
Figure 6: Global Neurology Market for Enzyme Inhibitors Drugs, 2018-2024
Figure 7: Global Neurology Market for Other Anti-Parkinson’s Drugs, 2018-2024
Figure 8: Global Neurology Market Share for Anti-Parkinson's Drugs, by Region, 2018
Figure 9: North American Neurology Market for Anti-Parkinson's Drugs, 2018-2024
Figure 10: European Neurology Market for Anti-Parkinson's Drugs, 2018-2024
Figure 11: Asia-Pacific Neurology Market for Anti-Parkinson's Drugs, 2018-2024
Figure 12: South American Neurology Market for Anti-Parkinson's Drugs, 2018-2024
Figure 13: Middle Eastern and African Neurology Market for Anti-Parkinson's Drugs, 2018-2024
Figure 14: Global Market Share for Key Competitors of Anti-Parkinson’s Drugs, 2018
Figure 15: Global Neurology Market for Alzheimer AChEIs Drugs, 2018-2024
Figure 16: Global Neurology Market for Alzheimer NMDA Drugs, 2018-2024
Figure 17: Global Neurology Market Share for Alzheimer Drugs, by Region, 2018
Figure 18: North American Neurology Market for Alzheimer Drugs, 2018-2024
Figure 19: European Neurology Market for Alzheimer Drugs, 2018-2024
Figure 20: Rest of the World Neurology Market for Alzheimer Drugs, 2018-2024
Figure 21: Global Neurology Market Share for Antipsychotic Drugs, by Mechanism of Action, 2018
Figure 22: Global Neurology Market for Antipsychotic Drugs in D2 Antagonist, 2018-2024
Figure 23: Global Neurology Market for Antipsychotic Drugs in D2/5HT2A Antagonist, 2018-2024
Figure 24: Global Neurology Market for Antipsychotic Drugs in D2 Partial Agonist, 2018-2024
Figure 25: Global Neurology Market Share for Antipsychotic Drugs, by Region, 2018
Figure 26: North American Neurology Market for Antipsychotic Drugs, 2018-2024
Figure 27: European Neurology Market for Antipsychotic Drugs, 2018-2024
Figure 28: Asia-Pacific Neurology Market for Antipsychotic Drugs, 2018-2024
Figure 29: South American Neurology Market for Antipsychotic Drugs, 2018-2024
Figure 30: Middle Eastern and African Neurology Market for Antipsychotic Drugs, 2018-2024
Figure 31: Global Neurology Market Share for Antipsychotic Drugs, by Manufacturer, 2018
Figure 32: Global Neurology Market Share for Anti-Epileptic Drugs, by Segment, 2018
Figure 33: Global Neurology Market for First Generation Anti-Epileptic Drugs, 2018-2024
Figure 34: Global Neurology Market for Second Generation Anti-Epileptic Drugs, 2018-2024
Figure 35: Global Neurology Market for Third Generation Anti-Epileptic Drugs, 2018-2024
Figure 36: Global Neurology Market Share for Anti-Epileptic Drugs, by Region, 2018
Figure 37: North American Neurology Market for Anti-Epileptic Drugs, 2018-2024
Figure 38: European Neurology Market for Anti-Epileptic Drugs, 2018-2024
Figure 39: Asia-Pacific Neurology Market for Anti-Epileptic Drugs, 2018-2024
Figure 40: South American Neurology Market for Anti-Epileptic Drugs, 2018-2024
Figure 41: Middle Eastern and African Neurology Market for Anti-Epileptic Drugs, 2018-2024
Figure 42: Global Neurology Market Share for Anti-Epileptic Drugs, by Manufacturer, 2018
Figure 43: Global Neurology Market Share for ASD Therapeutics, by Label Information, 2018
Figure 44: Global Neurology Market for Labeled ASD Drugs, 2018-2024
Figure 45: Global Neurology Market for Off-label Pharmaceuticals ASD, 2018-2024
Figure 46: Global Neurology Market Share for ASD Therapeutics, by Region, 2018
Figure 47: North American Neurology Market for ASD Therapeutics, 2018-2024
Figure 48: European Neurology Market for ASD Therapeutics, 2018-2024
Figure 49: Rest of the World Neurology Market for ASD Therapeutics, 2018-2024
Figure 50: Global Neurology Market Share for Brain Tumor Therapeutics, by Therapy Type, 2018
Figure 51: Global Neurology Market for Brain Tumor Chemotherapy, 2018-2024
Figure 52: Global Neurology Market for Brain Tumor Targeted Therapy, 2018-2024
Figure 53: Targeted Therapy Types
Figure 54: Global Neurology Market Share for Brain Tumor Therapeutics, by Region, 2018
Figure 55: North American Neurology Market for Brain Tumor Therapeutics, 2018-2024
Figure 56: North American Incidence of Brain Tumors, 2018-2040
Figure 57: European Neurology Market for Brain Tumor Therapeutics, 2018-2024
Figure 58: European Incidence of Brain Tumors, 2018-2040
Figure 59: Asia-Pacific Neurology Market for Brain Tumor Therapeutics, 2018-2024
Figure 60: Asia-Pacific Incidence of Brain Tumors, 2018-2040
Figure 61: ROW Neurology Market for Brain Tumor Therapeutics, 2018-2024
Figure 62: Shares of Major Players in Brain Tumor Therapeutics Market, 2018

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abbvie
  • Astrazeneca Plc
  • Bristol-Myers Squibb Co.
  • Gedeon Richter Plc
  • Lupin Ltd.
  • Otsuka Holdings Co., Ltd.
  • MORE

The  increased government funding in neurology research and an ever-growing demand for research focused on drug discovery for development of novel therapies in neurological disorders are driving the growth of neurology market.The global market for psychotic disease is anticipated to grow at a slow rate during the forecast period. The slow growth rate is attributed primarily to the loss of patent exclusivity of branded drugs and the emergence of generic drugs. Manufacturers of branded drugs are likely to experience a decline in sales revenue due to the penetration of low-cost generic drugs in the market, which is likely to impact the growth of the market for antipsychotic drugs.

Reasons for Doing this Study

Global neurology market comprises of various therapeutics used for the treatment of different neurological disorders. The novel pipeline, patent expiry of blockbuster drug and new drug approval have influenced the neurology market and it is expected to grow during the forecast period. The biopharmaceutical companies are investing significantly in the development of innovative therapeutics for the treatment of neurological disorders. Government organizations are funding research and development activities related to neurology research. These factors are impacting the neurology market positively coupled with the growing prevalence of neurological disorders.

New approaches for the treatment of neurology related indications were pursued by pharmaceutical companies. This new drug with a novel mechanism of action or improved delivery system will provide a powerful new option to currently prescribed neurology medicines.

The global neurology market is growing due to a rise in the aging population, growing awareness regarding mental and neurological illness, increasing health insurance reforms and constant research and development in neurology by pharmaceutical companies. These factors along with technological advances such as biomarkers, 3D printed drugs, mobile applications and wearable technologies used to monitor and treat patients diagnosed with neurological disorders are expected to drive the neurology drugs industry.

The report provides the reader with a background on neurological disorders and therapeutics, analyzes the current factors influencing the market, provides decision-makers the tools that inform decisions about expansion and penetration in this market.

Note: Product cover images may vary from those shown
5 of 5
  • Abbvie
  • Acadia Pharmaceuticals, Inc.
  • Alembic Pharmaceuticals Ltd.
  • Alexza Pharmaceuticals
  • Alkermes Plc
  • Allergan Plc
  • Apotex, Inc.
  • Astrazeneca Plc
  • Aurobindo Pharma
  • Autism Therapeutics
  • Avanir Pharmaceuticals Inc.
  • Biogen
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Co.
  • Daiichi Sankyo Co., Ltd.
  • Dr. Reddy’S Laboratories Ltd.
  • Eisai Co. Ltd.
  • Eli Lilly And Co.
  • F. Hoffmann-La Roche Ag
  • Gedeon Richter Plc
  • Glaxosmithkline Plc
  • H. Lundbeck A/S
  • Immunocellular Therapeutics, Ltd.
  • Johnson & Johnson
  • Lannett Co., Inc.
  • Lupin Ltd.
  • Mallinckrodt
  • Merck & Co
  • Mylan Nv
  • Nextsource Biotechnology Llc
  • Novartis Ag
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Sanofi
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Sun Pharmaceutical Industries Ltd. (Sun Pharma)
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • UCB SA
  • United Therapeutics Corp.
Note: Product cover images may vary from those shown
Adroll
adroll